邻近类别 圖書 [1/1] 期刊論文 [327/330] 类别统计 近3年内发表的文件:16(8.94%) 含全文笔数:115(64.25%) 文件下载次数统计 下载大于0次:115(100.00%) 下载大于100次:112(97.39%) 全文下载总次数:39325(22.06%) 最后更新时间: 2024-12-01 10:33 上传排行 数据加载中..... 下载排行 数据加载中..... 最近上传 Single-cell RNA sequencing via Endo... Nivolumab plus ipilimumab (N plus I... Risk of type 2 diabetes mellitus an... Phase 1 studies of D07001-F4 and D0... Updated overall survival (OS) from ... Outcomes of post-immunotherapy dura... Updated overall survival (OS) from ... Updated results of the FOENIX-CCA2 ... Comparative genomic analysis and it... A phase II trial of nivolumab, gemc...

跳至: (选择年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (选择月份) January February March April May June July August September October November December 或输入年份:

由新到旧排序 由最旧的开始

显示项目76-100 / 179. (共8页) << < 1 2 3 4 5 6 7 8 > >> 每页显示[10|25|50]项目

日期	题名	關聯
2017-09	A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 617O.
2017-06-26	Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy	Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD - 018.
2017-06-26	CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD-017.
2017-05	The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM	Journal of Clinical Oncology. 2017 May;35:Meeting Abstract e15795.
2017-02	Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO	Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):303.
2017-02	A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer	Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):417.
2017-02	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial	Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):2.
2017-02	Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV	Journal of Clinical Oncology. 2017 Feb;35(4):Meeting Abstract 293.
2016-12	Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 221PD.
2016-12	Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 242P.
2016-12	Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 420P.
2016-11	Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer	Journal of Gastroenterology and Hepatology. 2016 Nov;31(Suppl. 3):245.
2016-10	Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-b	Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):259.
2016-10	Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with ge	Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):260.
2016-10	Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 622PD.
2016-10	Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 693P.
2016-10	CagA and NFAT co-operatively participate in the lymphomagenesis of gastric MALT lymphoma	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 933P.
2016-09	Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: Results from t	Annals of Oncology. 2016 Sep;27(Suppl. 4):Meeting Abstract B04.
2016-06	Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study	Annals of Oncology. 2016 Jun;27(Suppl. 2):ii84.
2016-06	Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine	Annals of Oncology. 2016 Jun;27(Suppl. 2):119.
2016-06	Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2016 Jun;27(Suppl. 2):110.
2016-05	Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine	Journal of Clinical Oncology. 2016 May;34(15, Suppl.):Meeting Abstract 4126.
2016-05	Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15740.
2016-05	Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number 4017.
2016-05	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15732.

显示项目76-100 / 179. (共8页) << < 1 2 3 4 5 6 7 8 > >> 每页显示[10|25|50]项目